Follow the latest coverage, related explainers and connected technology stories.
A study funded by Dexcom and published in the New England Journal of Medicine found that using the Dexcom G7 improved HbA1c levels and time in the target range among people with type 2 diabetes who do not use insulin. The findings come as Dexcom awaits a decision from CMS on expanding Medicare coverage for these devices.
UK-based Sava Technologies raised $36 million in a Series B round led by Ascensia Diabetes Care, which also received exclusive rights to market and distribute the sensor in Europe. The company aims to launch a wearable sensor after conducting a pivotal trial and seek CE marking within the next two years.
Google announced broad updates to the Google Health and Fitbit ecosystem, including the Health Guardian feature, improved automatic activity detection, and integrations with Flo Health, Abbott, MyFitnessPal, and Function Health. Some features require a Google Health Premium subscription, while the tools remain not intended for medical diagnosis or treatment.
Beta Bionics has received U.S. Food and Drug Administration clearance for the Mint wearable insulin pump, which is worn for three days and holds 200 units of insulin. The company plans to launch it in the United States during the first quarter of 2027 through pharmacy channels, opening direct competition with Insulet.
Results from the FlexPulse IDE study showed that Abbott’s TactiFlex Duo catheter, which combines pulsed-field ablation and radiofrequency ablation, achieved efficacy and safety after one year of treating patients with paroxysmal atrial fibrillation. The company plans to use the data as the basis for submitting an application to the FDA to market the catheter in the United States.
Abbott has received the European CE mark for the Amulet 360, an upgraded version of its device for closing the left atrial appendage in certain patients with atrial fibrillation in order to reduce the risk of stroke. The company is preparing to expand the device’s use in European countries in the coming weeks, amid direct competition with Boston Scientific’s Watchman device.
Dexcom and Abbott are awaiting a CMS decision that could expand Medicare coverage for continuous glucose monitoring devices to include patients with type 2 diabetes who do not use insulin. Dexcom expects the decision before the end of 2026, with potential coverage beginning in mid-2027.
Boston Scientific disclosed a cyberattack that caused a network outage and disrupted business systems and technologies supporting the processing and shipment of customer orders worldwide. The company is still investigating the incident and has not yet determined its full scope or financial impact.
The U.S. Food and Drug Administration granted Abbott de novo authorization for the Libre Duo 10 Day wearable sensor, which can continuously monitor glucose and ketones in people with diabetes. The company plans to launch it in the United States during 2026, while its price and insurance coverage remain undisclosed.
The medical device sector experienced a series of cyberattacks throughout 2026 affecting Stryker, Medtronic, Abbott, Intuitive Surgical, and other companies. The effects ranged from disruptions to manufacturing and shipping to the exposure of patient and employee data, while some companies are still dealing with the aftermath of the incidents.
Abbott is preparing to launch Libre Duo, a sensor that combines glucose and ketone measurement, after receiving the CE mark and submitting an application to the FDA. The device raises practical questions about eligible populations, interpreting readings, educating users, cost, and the limits of relying on ketones alone.